Telomir Pharmaceuticals
TELO
43 hedge funds and large institutions have $3.51M invested in Telomir Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 16 closing their positions.
2% more funds holding
Funds holding: 42 → 43 (+1)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
2.97% less ownership
Funds ownership: 12.41% → 9.43% (-3%)
33% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 15
71% less capital invested
Capital invested by funds: $11.9M → $3.51M (-$8.42M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$573K |
| 2 |
Goldman Sachs
New York
|
+$297K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$175K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$149K |
| 5 |
Jane Street
New York
|
+$115K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.92M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$537K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$324K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$259K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$150K |
TELO Hedge Fund Activity: Q2 2025 in Review
43 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Telomir Pharmaceuticals (TELO) for Q2 2025, worth a combined $3.51M — down 71% from $11.9M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TELO positions and 16 closed out — a net gain of 1 holder — while 10 added to existing stakes and 15 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $573K. The largest seller was BlackRock, cutting an estimated $1.92M.
- 43 institutional investors held Telomir Pharmaceuticals (TELO) as of Q2 2025, up from 42 in Q1 2025.
- Funds reported $3.51M of Telomir Pharmaceuticals stock for Q2 2025, down 71% quarter-over-quarter.
- 17 funds opened new Telomir Pharmaceuticals positions in Q2 2025 and 16 closed out, a net change of +1 holder.
- The largest Telomir Pharmaceuticals buyer in Q2 2025 was Millennium Management, an estimated $573K added.
- The largest Telomir Pharmaceuticals seller in Q2 2025 was BlackRock, an estimated $1.92M sold.
Based on aggregated 13F filings for Q2 2025.